

DEPARTMENT OF DEFENSE

Defense Health Agency

Intent to Grant an Exclusive Option to License a U.S. Government-Owned Invention

AGENCY: Defense Health Agency, DoD.

ACTION: Notice.

SUMMARY: In accordance with applicable laws and regulations, announcement is made of the intent to grant an exclusive option to license within a field of use.

ADDRESSES: Commander, U.S. Army Medical Research and Development Command,
ATTN: Director, Office of Research and Technology Applications, 1520 Freedman Drive, Suite
227, Fort Detrick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: Dr. Paul Michaels, Office of Research &
Technology Applications, (301) 619-4145. For patent issues, Ms. Leigh Callander, Supervisory
Patent Attorney, (301) 619-7808.

SUPPLEMENTARY INFORMATION: In accordance with 35 U.S.C. 209 (e) and 37 CFR
404.7 (a)(1)(i), announcement is made of the intent to grant an exclusive option within a field of
use, for commercial evaluation purposes to Shigella-related technologies including: U.S. Patent
7,759,106, U.S. Patent 8,986,708, U.S. Patent 9,320,789, and U.S. Patent 10,881,684 entitled
“Artificial Invaplex Vaccine Formulated with Deacylated Lipopolysaccharide” to PATH, a non-
profit organization having its offices at 2201 Westlake Ave Suite 200, Seattle, Washington
98121.

Anyone wishing to object to grant of this option can file written objections along with
supporting evidence, if any, within 15 days from the date of this publication. Written objections

are to be filed with the Director, Office of Research and Technology Applications (see **ADDRESSES**).